Mechanisms of NF-κB p65 and strategies for therapeutic manipulation
- PMID: 30464573
- PMCID: PMC6217131
- DOI: 10.2147/JIR.S140188
Mechanisms of NF-κB p65 and strategies for therapeutic manipulation
Abstract
The transcription factor NF-κB is a critical regulator of immune and inflammatory responses. In mammals, the NF-κB/Rel family comprises five members: p50, p52, p65 (Rel-A), c-Rel, and Rel-B proteins, which form homo- or heterodimers and remain as an inactive complex with the inhibitory molecules called IκB proteins in resting cells. Two distinct NF-κB signaling pathways have been described: 1) the canonical pathway primarily activated by pathogens and inflammatory mediators, and 2) the noncanonical pathway mostly activated by developmental cues. The most abundant form of NF-κB activated by pathologic stimuli via the canonical pathway is the p65:p50 heterodimer. Disproportionate increase in activated p65 and subsequent transactivation of effector molecules is integral to the pathogenesis of many chronic diseases such as the rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and even neurodegenerative pathologies. Hence, the NF-κB p65 signaling pathway has been a pivotal point for intense drug discovery and development. This review begins with an overview of p65-mediated signaling followed by discussion of strategies that directly target NF-κB p65 in the context of chronic inflammation.
Keywords: NF-κB; inflammation; therapy.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures


Similar articles
-
Multiple redox regulation in NF-kappaB transcription factor activation.Biol Chem. 1997 Nov;378(11):1237-45. Biol Chem. 1997. PMID: 9426183 Review.
-
Regulation of intercellular adhesion molecule-1 gene by tumor necrosis factor-alpha is mediated by the nuclear factor-kappaB heterodimers p65/p65 and p65/c-Rel in the absence of p50.Cell Growth Differ. 1997 Mar;8(3):335-42. Cell Growth Differ. 1997. PMID: 9056676
-
Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA.Nature. 1998 Jan 22;391(6665):410-3. doi: 10.1038/34956. Nature. 1998. PMID: 9450761
-
Despite inhibition of nuclear localization of NF-kappa B p65, c-Rel, and RelB, 17-beta estradiol up-regulates NF-kappa B signaling in mouse splenocytes: the potential role of Bcl-3.J Immunol. 2007 Aug 1;179(3):1776-83. doi: 10.4049/jimmunol.179.3.1776. J Immunol. 2007. PMID: 17641044
-
Nuclear factor-kappaB1: regulation and function.Int J Biochem Cell Biol. 2008;40(8):1425-30. doi: 10.1016/j.biocel.2007.05.004. Epub 2007 May 17. Int J Biochem Cell Biol. 2008. PMID: 17693123 Review.
Cited by
-
Protective Effects of Sitagliptin on Streptozotocin-Induced Hepatic Injury in Diabetic Rats: A Possible Mechanisms.Diseases. 2023 Dec 18;11(4):184. doi: 10.3390/diseases11040184. Diseases. 2023. PMID: 38131990 Free PMC article.
-
Phytochemical Composition Antioxidant and Anti-Inflammatory Activity of Artemisia dracunculus and Artemisia abrotanum.Antioxidants (Basel). 2024 Aug 20;13(8):1016. doi: 10.3390/antiox13081016. Antioxidants (Basel). 2024. PMID: 39199260 Free PMC article.
-
Distribution of Immunomodulation, Protection and Regeneration Factors in Cleft-Affected Bone and Cartilage.Diagnostics (Basel). 2024 Oct 4;14(19):2217. doi: 10.3390/diagnostics14192217. Diagnostics (Basel). 2024. PMID: 39410621 Free PMC article.
-
Picroside II suppresses chondrocyte pyroptosis through MAPK/NF-κB/NLRP3 signaling pathway alleviates osteoarthritis.PLoS One. 2024 Aug 29;19(8):e0308731. doi: 10.1371/journal.pone.0308731. eCollection 2024. PLoS One. 2024. PMID: 39208260 Free PMC article.
-
Naringin Inhibits Apoptosis Induced by Cyclic Stretch in Rat Annular Cells and Partially Attenuates Disc Degeneration by Inhibiting the ROS/NF-κB Pathway.Oxid Med Cell Longev. 2022 Feb 23;2022:6179444. doi: 10.1155/2022/6179444. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35251479 Free PMC article.
References
-
- Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3(1):17–26. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials